Ángel Pérez Sempere
A5045334308- Multiple Sclerosis Research Studies
- Peripheral Neuropathies and Disorders
- Polyomavirus and related diseases
- Epilepsy research and treatment
- Rheumatoid Arthritis Research and Therapies
- Health Systems, Economic Evaluations, Quality of Life
- Neurological disorders and treatments
- Parkinson's Disease Mechanisms and Treatments
- Pharmacological Effects and Toxicity Studies
- Patient-Provider Communication in Healthcare
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Neurology and Historical Studies
- Systemic Lupus Erythematosus Research
- Migraine and Headache Studies
- Glycogen Storage Diseases and Myoclonus
- Healthcare Systems and Technology
- Neurological and metabolic disorders
- Clinical Reasoning and Diagnostic Skills
- Parkinson's Disease and Spinal Disorders
- Metabolism and Genetic Disorders
- Pharmaceutical studies and practices
- Trigeminal Neuralgia and Treatments
- Traumatic Brain Injury and Neurovascular Disturbances
- Botulinum Toxin and Related Neurological Disorders
- Genetic Neurodegenerative Diseases
Universitat de Miguel Hernández d'Elx
2020-2024
Instituto de investigación sanitaria y biomédica de Alicante
2021-2024
Hospital General Universitario de Alicante Doctor Balmis
2015-2024
Instituto de Neurociencias
2023
Hospital Marina Baixa
2016
University of Alicante
2015
Hospital Vega Baja
1996-2011
Centro de Investigación Biomédica en Red
2009
Instituto de Salud Carlos III
2009
Centre for Biomedical Network Research on Rare Diseases
2008-2009
To (1) determine the value of recently proposed criteria neuromyelitis optica (NMO) spectrum disorder (NMOSD) that unify patients with NMO and those limited forms (NMO/LF) aquaporin-4 immunoglobulin G (AQP4-IgG) antibodies; (2) investigate clinical significance serologic status in NMO.This was a retrospective, multicenter study 181 fulfilling 2006 (n = 127) or NMO/LF AQP4-IgG 54). myelin oligodendrocyte glycoprotein (MOG-IgG) antibodies were tested using cell-based assays.Patients mainly...
Autologous hematopoietic stem cell transplant (AHSCT) is available for treatment of highly active multiple sclerosis (MS).
<h3>Objective</h3> To evaluate the safety and efficacy of cladribine tablets in patients still experiencing active relapsing MS despite interferon (IFN)-β treatment. <h3>Methods</h3> A 96-week phase II study, randomizing treated with IFN-β to 3.5 mg/kg/IFN-β or placebo/IFN-β. Patients were receive placebo/IFN-β a 2:1 ratio (n = 172) exploratory outcomes being assessed. <h3>Results</h3> Adverse events (AEs) serious AEs similar across treatment groups, except lymphopenia. Fifty 124 (40.3%)...
Multiple sclerosis patients who discontinue using natalizumab are at risk of a rebound in disease activity. However, the optimal alternative therapy is not currently known.We report on clinical and MRI data patient safety group relapsing-remitting multiple tested seropositive for JC virus have switched from to fingolimod because concerns regarding PML risks.The test antibodies was performed 18 were being treated with more than 1 year. Eight while seronegative continued natalizumab.After...
Background: Therapeutic inertia (TI) in multiple sclerosis (MS) is defined as the lack of treatment escalation when there evidence disease activity. Limited information available on physician-related factors influencing TI MS. The aim study was to evaluate whether physicians' risk preferences are associated with management MS by applying concepts from behavioral economics. Methods: A neurologists managing patients conducted Spain. Participants answered questions regarding 20 case-scenarios...
Abstract A questionnaire designed to screen Parkinson's disease (PD) in literate populations has been developed. It consists of nine questions, self‐administered at medical facilities or by mail, and a scale weights for ascribing scores specific questions when the answer is positive. The were chosen be symptom PD determined from answers provided 37 patients neurological outpatient clinic. sensitivity was tested on different population same clinic−50 individuals‐and specificity group 100...
Abstract We assessed the prevalence of Parkinson's disease in Cantalejo, Spain. In 1994, we screened 1,579 persons (age ≥ 40 years) using a high‐sensitivity method. Cases fulfilling established clinical criteria were followed for minimum 3 years. Prevalences compared with those from other door‐to‐door surveys. detected 27 individuals parkinsonism, 20 whom had disease. The increased age and, when age‐adjusted to European standards, was 9.01 per 1,000 years and over; 10.78 men 5.23 women). Of...
The objective in this paper is to compare the cumulative incidence and density of therapy-related acute myeloid leukaemia two cohorts patients with multiple sclerosis treated mitoxantrone, previously reported data literature. Six new cases were observed by prospectively following Spanish series 142 88 worsening relapsing secondary-progressive disease mitoxantrone. A literature review shows 32 further reported, 65.6% which are promyelocytic leukaemia. Five fulfilled diagnostic criteria for...
The management of multiple sclerosis (MS) is rapidly changing by the introduction new and more effective disease-modifying agents. importance risk stratification was confirmed results on disease progression predicted different score systems. Despite these advances, we know very little about medical decisions under uncertainty in MS. goal this study to i) identify whether overconfidence, tolerance risk/uncertainty, herding influence decisions, ii) evaluate frequency therapeutic inertia...
Abstract Objective Pivotal trial have shown that patients with multiple sclerosis (MS) receiving ocrelizumab had better outcomes. However, data on in clinical practice are limited. The aim of this study was to evaluate the preliminary safety profile and effectiveness treatment for a real‐world setting. Methods We conducted retrospective including consecutive from nine public hospitals south‐eastern Spain who received after it approved. Results A total 228 MS were included (144...
Abstract In multiple sclerosis, treatment start or switch is prompted by evidence of disease activity. Whilst immunomodulatory therapies reduce activity, the time required to attain maximal effect unclear. this study we aimed develop a method that allows identification manifest fully and clinically sclerosis treatments (‘therapeutic lag’) on clinical activity represented relapses progression-of-disability events. Data from two registries, MSBase (multinational) OFSEP (French), were used....
<h3>Objective</h3> To understand COVID-19 characteristics in people with multiple sclerosis (MS) and identify high-risk individuals due to their immunocompromised state resulting from the use of disease-modifying treatments. <h3>Methods</h3> Retrospective multicenter registry patients MS suspected or confirmed diagnosis available disease course (mild = ambulatory; severe hospitalization; critical intensive care unit/death). Cases were analyzed for associations between identifying risk...
A prospective study of 98 consecutive adults with a first seizure to determine the most important etiological factors and optimum diagnostics. 27 were thought have cryptogenic seizures. Main causes symptomatic seizures were: cerebral infarction, alcohol-withdrawal, CNS infections, tumors, vascular malformations, traumatism miscellanea. Eight infected by human immunodeficiency virus (HIV-1) representing 8.2% all patients 20% 15-45-year age group. CT disclosed structural lesions in 33 cases....
Objective: The aim of this study is to report the clinical profile and outcome longitudinally extensive transverse myelitis (LETM). Methods: We prospectively studied adult patients who presented with LETM from January 2008 December 2011. Information on demographic, course, magnetic resonance imaging (MRI) was collected. HLA-DRB1 genotype compared those 225 normal controls MS (228) neuromyelitis optica (NMO) (22). Results: In total, 23 (16 female) a median age 44.5 years (range: 20–77 years)...
Objective To assess patients’ preferences for a range of disease-modifying therapy (DMT) attributes in multiple sclerosis (MS). Design A cross-sectional observational study. Setting The data reported were from 17 MS units throughout Spain. Participants Adult patients with relapsing-remitting MS. Main outcome conjoint analysis was applied to preferences. total 221 completed survey 10 hypothetical DMT profiles developed using an orthogonal design and rating 1 (most acceptable) (least...
Geographical variations in the incidence and prevalence of multiple sclerosis have been reported globally. Latitude as a surrogate for exposure to ultraviolet radiation but also other lifestyle environmental factors are regarded drivers this variation. No previous studies evaluated geographical variation risk secondary progressive sclerosis, an advanced form that is characterized by steady accrual irreversible disability. We differences relation latitude country residence, modified...
Background: The prognostic significance of non-disabling relapses in people with relapsing-remitting multiple sclerosis (RRMS) is unclear. Objective: To determine whether early predict disability accumulation RRMS. Methods: We redefined mild MSBase as ‘non-disabling’, and moderate or severe ‘disabling’. used mixed-effects Cox models to compare 90-day confirmed events exclusively within 2 years RRMS diagnosis those no relapses; any disabling relapses. Analyses were stratified by...
Background and Purpose The aim of this study was to determine the incidence transient ischemic attacks (TIAs) minor strokes (MISs) in Segovia, Spain. Methods A 2-year prospective community-based register TIAs MISs established Segovia from February 16, 1992, 15, 1994. Every patient underwent a complete clinical evaluation cranial CT scan. Sex- age-specific rates with 95% confidence intervals (CIs) were calculated for all ages. Results total series included 235 patients; 103 suffered 132 MISs....
Objective To study the molecular genetic and clinical features of cerebral cavernous malformations (CCM) in a cohort Spanish patients. Methods We analyzed CCM1, CCM2, CCM3 genes by MLPA direct sequencing exons intronic boundaries 94 familial forms 41 sporadic cases CCM patients extraction. When available, RNA studies were performed seeking for alternative or cryptic splicing. Results A total 26 pathogenic mutations, 22 which predict truncated proteins, identified 29 three cases. The...
Objectives: The aim of this study was to describe the tolerability, safety, and effectiveness ocrelizumab for primary progressive multiple sclerosis (PPMS) relapsing (RMS) in a clinical practice setting. Methods: In retrospective observational study, we analyzed MRI data all patients with PPMS RMS who had received at least one infusion two health areas south-eastern Spain. Patients involved any trial those follow-up shorter than 6 months were excluded. Results: cohort included 70 (42 women)...
SYNOPSIS Twenty‐seven patients with acute severe headache of recent onset were prospectively recruited in the Emergency Room. Mean duration was 61 hours. CT scan disclosed subarachnoid bleeding 4 and spinal tap revealed hemorrhage (SAH) 5 normal scan. In most SAH cases pain bilateral, very intense involving occipital region. Four these had doubtful or no nuchal rigidity one, improved while every case an (if normal) a lumbar puncture are warranted to help rule out SAH.